Plasma NT pro-BNP, hs-CRP and big-ET levels at admission as prognostic markers of survival in hospitalized patients with dilated cardiomyopathy: a single-center cohort study

BMC Cardiovascular Disorders

Wei Hua³  Ligang Ding³  Yang Wang³  Feng Gan⁴  Chengzhi Chen¹  Xiaoping Li² 

[1] Department of Cardiology, Liuyang People Hospital, Liuyang 421001, China;Department of Cardiology, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu 610072, China;Cardiac Arrhythmia Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China;Department of Cardiology, Beijing Aerospace General Hospital, Beijing 100037, China

关键词: Prognosis;    Big-endothelin;    Hs-CRP;    NT pro-BNP;    Dilated cardiomyopathy;   

Others  :  848397
DOI  :  10.1186/1471-2261-14-67

 received in 2014-02-05, accepted in 2014-05-06,  发布年份 2014

【 摘 要 】

Background

Circulating N-terminal pro-B-type natriuretic peptide (NT pro-BNP), high- sensitivity C-reactive protein (hs-CRP) and big endothelin (big-ET) have been shown to be increased in heart failure and to contribute to both hemodynamic deterioration and cardiovascular remodeling. Here, we examined the prognostic value of the three neurohormones at admission in a population of hospitalized patients with dilated cardiomyopathy (DCM).

Methods and results

This cohort study was undertaken in 622 hospitalized patients with DCM in Fuwai Hospital from January 2005 to September 2011 (female 26.5%, 51.4 ± 14.6 years old). Standard demographics, echocardiography and routine blood samples were obtained shortly after admission. NT pro-BNP, hs-CRP and big-ET were measured, and their concentrations in relation to all-cause mortality were assessed through a mean follow-up of 2.6 ± 1.6 years. Kaplan-Meier curves showed that the all-cause mortality rates were higher in patients with NT pro-BNP > 2247 pmol/L compared to patients with NT pro-BNP < 2247 pmol/L (11.9% vs 34.8%, log-rank χ² = 35.588, P < 0.001), in patients with hs-CRP > 3.90 mg/L compared to patients with hs-CRP < 3.90 mg/L (12.8% vs 33.6%, log-rank χ² = 39.662, P < 0.001) and in patients with big-ET > 0.95 pmol/L compared to patients with big-ET <0.95 pmol/L (12.5% vs 31.0%, log-rank χ² = 17.890, P < 0.001). High circulating concentrations of NT pro-BNP (HR 2.217, 95% CI 1.015-4.846, P = 0.046) and hs-CRP (HR 1.922, 95% CI 1.236-2.988, P = 0.004), but not big-ET, in addition to left atrial diameter and fasting blood glucose, were independent predictors of the outcome defined as all-cause mortality.

Conclusions

In a large population of patients with DCM, the circulating concentrations of NT pro-BNP and hs-CRP, but not big-ET, were independent markers of all-cause mortality.

【 授权许可】

   
2014 Li et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Nagagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I: Rapid transcriptional activation and early mRNA turnover of BNP in cardiocyte hypertrophy: evidence for BNP as an “emergency” cardiac hormone against ventricular overload. J Clin Invest 1995, 96:1280-1287.
• [2]Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, Mukoyama M, Nakao K, Imura H: Different secretion pattern of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993, 87:464-469.
• [3]Clerico A, Recchia FA, Passino C, Emdin M: Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 2006, 290:H17-H29.
• [4]Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Ornland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA: Rapid measurement of b-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161-167.
• [5]McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG, Duc P, Westheim A, Ornland T, Knudsen CW, Storrow AB, Abraham WT, Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS: B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from breathing not properly (BNP) Multinational Study. Circulation 2002, 106:416-422.
• [6]Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M: Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 2007, 49:1943-1950.
• [7]Schou M, Gustafsson F, Corell P, Kistorp CN, Kjaer A, Hildebrandt PR: The relationship between N-terminal pro-brain natriuretic peptide and risk for hospitalization and mortality is curvilinear in patients with chronic heart failure. Am Heart J 2007, 154:123-129.
• [8]Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, Clopton P, Maisel A: A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001, 37:386-391.
• [9]Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB: Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997, 349(9050):462-466.
• [10]Ridker PM: High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001, 103:1813-1818.
• [11]Mendall MA, Strachan DP, Butland BK, Ballam L, Morris J, Sweetnam PM, Elwood PC: Creactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000, 21:1584-1590.
• [12]Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM: C-reactive protein and the risk of developing hypertension. JAMA 2003, 290:2945-2951.
• [13]Pye M, Rae AP, Cobbe SM: Study of serum Creactive protein concentration in cardiac failure. Br Heart J 1990, 63:228-230.
• [14]Alonso-Martínez JL, Llorente-Diez B, Echegaray-Agara M, Olaz-Preciado F, Urbieta-Echezarreta M, González-Arencibia C: C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 2002, 4:331-336.
• [15]Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, Feng AN, Young MS, Lin SJ: Independent prognostic value of elevated high-sensitivity Creactive protein in chronic heart failure. Am Heart J 2004, 147(5):931-938.
• [16]Steele IC, Nugent AM, Maguire S, Hoper M, Campbell G, Halliday MI, Nicholls DP: Cytokine profile in chronic cardiac failure. Eur J Clin Invest 1996, 26:1018-1022.
• [17]Pietilä KO, Harmoinen AP, Jokiniitty J, Pasternack AI: Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J 1996, 17:1345-1349.
• [18]McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ: Plasma endothelin in chronic heart failure. Circulation 1992, 85:1374-1379.
• [19]Pacher R, Bergler-Klein J, Globits S, Teufelsbauer H, Schuller M, Krauter A, Ogris E, Rödler S, Wutte M, Hartter E: Plasma big endothelin-1 concentration in congestive heart failure patients with or without heart failure. Am J Cardiol 1993, 71:1293-1299.
• [20]Wei CM, Lerman A, Rodeheffer RJ, McGregor CG, Brandt RR, Wright S, Heublein DM, Kao PC, Edwards WD, Burnett JC Jr: Endothelin in human congestive heart failure. Circulation 1994, 89:1580-1586.
• [21]Tsutamoto T, Hisanaga T, Fukai D, Wada A, Maeda Y, Maeda K, Kinoshita M: Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol 1995, 76:803-808.
• [22]Pousset F, Isnard R, Lechat P, Kalotka H, Carayon A, Maistre G, Escolano S, Thomas D, Komajda M: Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 1997, 18:254-258.
• [23]Van Beneden R, Gurné O, Selvais PL, Ahn SA, Robert AR, Ketelslegers JM, Pouleur HG, Rousseau MF: Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study. J Cardiac Fail 2004, 10:490-495.
• [24]Pacher R, Stanek B, Hülsmann M, Koller-Strametz J, Berger R, Schuller M, Hartter E, Ogris E, Frey B, Heinz G, Maurer G: Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996, 27:633-641.
• [25]Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB, American Heart Association; Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups: Council on Epidemiology and Prevention. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006, 113:1807-1816.
• [26]Braunwald E: Biomarkers in heart failure. N Engl J Med 2008, 358:2148-2159.
• [27]Maeda K, Takayoshi T, Wada A, Hisanaga T, Kinoshita M: Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998, 135:825-832.
• [28]Clerico A, Iervasi G, Del Chicca MG, Emdin M, Maffei S, Nannipieri M, Sabatino L, Forini F, Manfredi C, Donato L: Circulating levels of cardiac specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest 1998, 21:170-179.
• [29]Wallen T, Landahl S, Hedner T, Nako K, Saito Y: Brain natriuretic peptide predicts mortality in the elderly. Heart 1997, 77:264-267.
• [30]Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A: N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004, 110:2168-2174.
• [31]Bayés-Genís A, Lopez L, Zapico E, Cotes C, Santaló M, Ordonez-Llanos J, Cinca J: NT-ProBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality. J Card Fail 2005, 11:S3-S8.
• [32]Cournot M, Mourre F, Castel F, Ferrieres J, Destrac S: Optimization of the use of B-type natriuretic peptide levels for risk stratification at discharge in elderly patients with decompensated heart failure. Am Heart J 2008, 155:986-991.
• [33]Waldo SW, Beede J, Isakson S, Villard-Saussine S, Fareh J, Clopton P, Fitzgerald RL, Maisel AS: Pro-B-type natriuretic peptide levels in acute decompensated heart failure. J Am Coll Cardiol 2008, 51:1874-1882.
• [34]Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, Aupetit JF, Aumont MC, Galinier M, Eicher JC, Cohen-Solal A, Juillière Y: Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007, 49(16):1733-1739.
• [35]Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000, 355(9210):1126-1130.
• [36]Bistola V, Parissis JT, Paraskevaidis I, Panou F, Nikolaou M, Ikonomidis I, Flessas N, Filippatos G, Iliodromitis E, Kremastinos DT: Prognostic value of tissue Doppler right ventricular systolic and diastolic function indexes combined with plasma B-type natriuretic Peptide in patients with advanced heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2010, 105(2):249-254.
• [37]Tigen K, Karaahmet T, Cevik C, Gurel E, Pala S, Mutlu B, Basaran Y: Prognostic utility of right ventricular systolic functions assessed by tissue doppler imaging in dilated cardiomyopathy and its correlation with plasma NT-pro-BNPlevels. Congest Heart Fail 2009, 15(5):234-239.
• [38]Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, Cassani G, Visioli O: Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995, 92:1479-1486.
• [39]MacGowan GA, Mann DL, Kormos RL, Feldman AM, Murali S: Circulating interleukin-6 in severe heart failure. Am J Cardiol 1997, 79:1128-1131.
• [40]Clark DJ, Cleman MW, Pfau SE, Rollins SA, Ramahi TM, Mayer C, Caulin-Glaser T, Daher E, Kosiborod M, Bell L, Setaro JF: Serum complement activation in congestive heart failure. Am Heart J 2001, 141:684-690.